logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma – second-line

< Back

Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma – second-line

Drugs

Cancer and Palliative Care

October 2020


Lisocabtagene maraleucel is in clinical development for the treatment of adult patients with high-risk, relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). In NHL, the affected lymphocytes start to multiply abnormally and begin to collect in certain parts of the body such as the lymph nodes. Aggressive or high-grade lymphomas tend to grow very quickly. Relapsed means the lymphoma has responded to treatment but then returns, and refractory means the lymphoma has not responded to the initial treatment. Treatment options for relapsed/refractory aggressive B-cell lymphoma are limited.
Lisocabtagene maraleucel is administered intravenously. It contains the patient’s white blood cells (T-cells) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). The CAR T-cells attach to a particular protein called CD19 on the surface of cancer cells resulting in the death of these cells. If licensed, lisocabtagene maraleucel will offer a treatment option for adult patients with high-risk, relapsed or refractory aggressive B-cell NHL.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts